Sarah Cook-Scalise Selected Research

bedaquiline (R207910)

1/2022	Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
12/2021	Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sarah Cook-Scalise Research Topics

Disease

2	Extensively Drug-Resistant Tuberculosis 01/2022 - 12/2021
2	Tuberculosis (Tuberculoses) 12/2020 - 09/2019

Drug/Important Bio-Agent (IBA)

2	pretomanidIBA 01/2022 - 12/2021
2	bedaquiline (R207910)IBA 01/2022 - 12/2021
2	Linezolid (Zyvox)FDA Link 01/2022 - 12/2021
1	FluoroquinolonesIBA 12/2020
1	Rifampin (Rifampicin)FDA LinkGeneric 09/2019

Therapy/Procedure

1	Duration of Therapy 09/2019